Sarepta Therapeutics (NASDAQ:SRPT) Given New $80.00 Price Target at Scotiabank

Sarepta Therapeutics (NASDAQ:SRPT) had its price objective decreased by Scotiabank from $105.00 to $80.00 in a report published on Thursday morning,Benzinga reports. Scotiabank currently has a sector perform rating on the biotechnology company’s stock.

A number of other research analysts have also recently weighed in on SRPT. Piper Sandler dropped their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Needham & Company LLC restated a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $163.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday. HC Wainwright reiterated a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday. Finally, Royal Bank of Canada dropped their price objective on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $167.41.

Sarepta Therapeutics Trading Down 8.2 %

Shares of SRPT stock opened at $73.45 on Thursday. Sarepta Therapeutics has a fifty-two week low of $73.06 and a fifty-two week high of $173.25. The stock has a market cap of $7.13 billion, a P/E ratio of 58.76 and a beta of 0.79. The business has a fifty day simple moving average of $108.20 and a 200-day simple moving average of $118.54. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insider Activity

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company’s stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. Manchester Capital Management LLC lifted its position in Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares in the last quarter. Sunbelt Securities Inc. lifted its position in Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Sarepta Therapeutics during the 4th quarter worth approximately $36,000. Finally, Steward Partners Investment Advisory LLC lifted its position in Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 194 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.